As of August 31, 2026, 75,500 ordinary shares were acquired for a total amount of 303,794,000 yen. Up to 1,300,000 shares (3.14% of issued shares) are planned to be purchased on the market from May 12, 2026 to December 31, 2026. Cumulative total since the May 11, 2026 Board of Directors meeting is 75,500 shares for 30.3 million yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4547","jir_company_name":"Kissei Pharmaceutical Company, Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4547-20260903-01.pdf","jir_short_summary":"As of August 31, 2026, 75,500 ordinary shares were acquired for a total amount of 303,794,000 yen. Up to 1,300,000 shares (3.14% of issued shares) are planned to be purchased on the market from May 12, 2026 to December 31, 2026. Cumulative total since the May 11, 2026 Board of Directors meeting is 75,500 shares for 30.3 million yen.","jir_summary":"### Overview\nThis is a notice disclosing the status of share buyback under the Companies Act, with the target shares being our ordinary shares. The cumulative number of acquired shares is 75,500, and the total amount reaches 30.379,4000 yen. The acquisitions above are on an execution basis as of August 31, 2026, and further purchases are planned through market purchases. At the May 11, 2026 Board resolution, a cap of 1,300,000 shares (3.14% of issued shares) and a cap of 6.0 billion yen were set, with a period from May 12, 2026 to December 31, 2026.\n\n### Impact on shareholders and future policy\nThe current share buyback aims to mitigate dilution and strengthen shareholder returns. The cumulative acquisition volume to date remains modest relative to the cap. Depending on future additional acquisitions, it may affect investor perception of shareholder returns stability and support for the stock price. Since the acquisition period is long (May 12, 2026 to December 31, 2026), progress is expected to be disclosed as appropriate.","jir_financial_highlights":"Total number of acquired shares: 75,500 shares (Unknown)\nTotal amount of acquisition value: 303,794,000 yen (Unknown)\nAcquisition period: August 1, 2026 to August 31, 2026 (Unknown)\nMethod of acquisition: Market purchases (Unknown)","jir_category":"","jir_hashtags":"#Kissei Pharmaceutical Company, Limited, #ShareBuyback","jir_key_figures":"75,500 shares: acquired shares\n303,794,000 yen: total amount of acquisition value\n1,300,000 shares: cap on shares (as per resolution)","jir_meta_title":"\u3010Kissei Pharmaceutical Company, Limited\u3011Notice on Share Buyback Status | September 3, 2026","jir_meta_description":"Disclosure of Kissei Pharmaceutical Company's share buyback status. Acquisition of 75,500 shares for a total of 30,379,4000 yen; current cumulative and future policy regarding up to 1,300,000 shares (3.14%).","jir_og_title":"\u3010Kissei Pharmaceutical Company, Limited\u3011Notice on Share Buyback Status","jir_og_description":"Report on Kissei Pharmaceutical Company's share buyback status. Cumulative 75,500 shares acquired, total amount 30,379,4000 yen. Future policy also discussed.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8930,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-110559","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n